Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.

Endocrine - 1 Jul 2024

Sang Ye, Hu Guanghui, Xue Junyu, Chen Mengke, Hong Shubin, Liu Rengyun

Abstract excerpt

PURPOSE: Risk stratification based on somatic mutations in TERT promoter and BRAF/RAS has been well established for papillary thyroid cancer (PTC), and there is emerging evidence showed that TERT promoter methylation was frequently observed in thyroid cancer patients with adverse features. This study was aimed to comprehensive explore the prognostic value of BRAF/RAS mutations, TERT promoter mutations, and TERT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Methylation
Share to Prognosis
Share to Promoter Regions, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Risk Assessment

Share to Telomerase

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 38356100
DOI: 10.1007/s12020-024-03722-6

Genes

TERT
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.PMID 38356100Read ↗

Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.Semantic proximity Read ↗

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid CancerSemantic proximity Read ↗

TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.Semantic proximity Read ↗

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Semantic proximity Read ↗

Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness.Semantic proximity Read ↗

A six-genotype genetic prognostic model for papillary thyroid cancer.Semantic proximity Read ↗

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients.Semantic proximity Read ↗

Preoperative Co-Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence-Free Survival in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.Semantic proximity Read ↗

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.Semantic proximity Read ↗

Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single InstitutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.